Clinical Trial Update: 32P BioSiliconTM in Addition to Gemcitabine in Pancreatic Cancer [Phase 2]

View source ↗

Summary

Clinical trial update on a Phase 2 study evaluating 32P BioSilicon in combination with Gemcitabine for pancreatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• 32P BioSilicon (32P-labeled BioSilicon compound)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: pSiMedica Limited | Conditions: Pancreatic Cancer | Phase 2 | Status: UNKNOWN